{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T11:47:16Z","timestamp":1782906436781,"version":"3.54.5"},"reference-count":14,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,3,25]],"date-time":"2026-03-25T00:00:00Z","timestamp":1774396800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100001422","name":"American Society of Hematology","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100001422","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Blood Neoplasia"],"published-print":{"date-parts":[[2026,5]]},"DOI":"10.1016\/j.bneo.2026.100222","type":"journal-article","created":{"date-parts":[[2026,3,26]],"date-time":"2026-03-26T05:27:17Z","timestamp":1774502837000},"page":"100222","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"title":["Prioritized health outcomes for adolescents and young adults with acute lymphoblastic leukemia"],"prefix":"10.1016","volume":"3","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2062-3382","authenticated-orcid":false,"given":"Ian J.","family":"Saldanha","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4017-4561","authenticated-orcid":false,"given":"Yuliia","family":"Sereda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ghid","family":"Kanaan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-1357-1088","authenticated-orcid":false,"given":"Htun Ja","family":"Mai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John W.","family":"Melson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0975-391X","authenticated-orcid":false,"given":"Teruhiko","family":"Terasawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1334-3670","authenticated-orcid":false,"given":"Sumit","family":"Gupta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8517-8198","authenticated-orcid":false,"given":"Kristen M.","family":"O\u2019Dwyer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julie A.","family":"Wolfson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wendy","family":"Stock","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew C.","family":"Cheung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4376-7290","authenticated-orcid":false,"given":"Ethan M.","family":"Balk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.bneo.2026.100222_bib1","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1089\/jayao.2010.0001","article-title":"Treatment of acute lymphoblastic leukemia in adolescents and young adults","volume":"1","author":"Mohan","year":"2011","journal-title":"J Adolesc Young Adult Oncol"},{"key":"10.1016\/j.bneo.2026.100222_bib2","doi-asserted-by":"crossref","DOI":"10.1182\/bloodadvances.2021006469","article-title":"ASH 2026 guidelines for frontline management of acute lymphoblastic leukemia in adolescents and young adults","author":"DuVall","year":"2026","journal-title":"Blood Adv"},{"key":"10.1016\/j.bneo.2026.100222_bib3","doi-asserted-by":"crossref","DOI":"10.1182\/bloodadvances.2021006479","article-title":"ASH 2026 guidelines for management of relapsed\/refractory disease in adolescents and young adults with ALL","author":"O'Dwyer","year":"2026","journal-title":"Blood Adv"},{"key":"10.1016\/j.bneo.2026.100222_bib4","doi-asserted-by":"crossref","DOI":"10.1182\/bloodadvances.2025018736","article-title":"Pediatric-inspired regimens & HSCT for adolescents & young adults with acute lymphoblastic leukemia: systematic reviews","author":"Sereda","year":"2026","journal-title":"Blood Adv"},{"key":"10.1016\/j.bneo.2026.100222_bib5","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1186\/1745-6215-13-132","article-title":"Developing core outcome sets for clinical trials: issues to consider","volume":"13","author":"Williamson","year":"2012","journal-title":"Trials"},{"issue":"4","key":"10.1016\/j.bneo.2026.100222_bib6","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1016\/j.jclinepi.2010.09.012","article-title":"GRADE guidelines: 2. Framing the question and deciding on important outcomes","volume":"64","author":"Guyatt","year":"2011","journal-title":"J Clin Epidemiol"},{"key":"10.1016\/j.bneo.2026.100222_bib7","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1016\/j.jclinepi.2017.12.020","article-title":"A taxonomy has been developed for outcomes in medical research to help improve knowledge discovery","volume":"96","author":"Dodd","year":"2018","journal-title":"J Clin Epidemiol"},{"key":"10.1016\/j.bneo.2026.100222_bib8","article-title":"A methodological approach for assessing the uptake of core outcome sets using ClinicalTrials.gov: findings from a review of randomised controlled trials of rheumatoid arthritis","volume":"357","author":"Kirkham","year":"2017","journal-title":"Bmj"},{"key":"10.1016\/j.bneo.2026.100222_bib9","series-title":"Cochrane Handbook for Systematic Reviews of Interventions","author":"Higgins","year":"2019"},{"key":"10.1016\/j.bneo.2026.100222_bib10","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1016\/j.jclinepi.2022.06.016","article-title":"Review finds core outcome set uptake in new studies and systematic reviews needs improvement","volume":"150","author":"Williamson","year":"2022","journal-title":"J Clin Epidemiol"},{"issue":"4","key":"10.1016\/j.bneo.2026.100222_bib12","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1182\/blood-2016-08-733196","article-title":"Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel","volume":"129","author":"D\u00f6hner","year":"2017","journal-title":"Blood"},{"issue":"suppl 1","key":"10.1016\/j.bneo.2026.100222_bib13","doi-asserted-by":"crossref","first-page":"5285","DOI":"10.1182\/blood-2022-157549","article-title":"Pan-stakeholder core outcome set (COS) definition for hematological malignancies within the framework of harmony and harmony PLUS projects","volume":"140","author":"Lang","year":"2022","journal-title":"Blood"},{"issue":"11","key":"10.1016\/j.bneo.2026.100222_bib14","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.1002447","article-title":"Core outcome set-STAndards for development: the COS-STAD recommendations","volume":"14","author":"Kirkham","year":"2017","journal-title":"PLoS Med"},{"key":"10.1016\/j.bneo.2026.100222_bib15","doi-asserted-by":"crossref","DOI":"10.1016\/j.jclinepi.2024.111311","article-title":"Representation of published core outcome sets in practice guidelines","volume":"169","author":"Rhodes","year":"2024","journal-title":"J Clin Epidemiol"}],"container-title":["Blood Neoplasia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2950328026000336?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2950328026000336?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,20]],"date-time":"2026-05-20T16:24:10Z","timestamp":1779294250000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2950328026000336"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5]]},"references-count":14,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,5]]}},"alternative-id":["S2950328026000336"],"URL":"https:\/\/doi.org\/10.1016\/j.bneo.2026.100222","relation":{},"ISSN":["2950-3280"],"issn-type":[{"value":"2950-3280","type":"print"}],"subject":[],"published":{"date-parts":[[2026,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Prioritized health outcomes for adolescents and young adults with acute lymphoblastic leukemia","name":"articletitle","label":"Article Title"},{"value":"Blood Neoplasia","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bneo.2026.100222","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 American Society of Hematology. Published by Elsevier Inc. Licensed under Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0), permitting only noncommercial, nonderivative use with attribution. All other rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"100222"}}